Spyre Therapeutics, Inc. (SYRE)
72.39
-2.53
(-3.38%)
USD |
NASDAQ |
May 18, 10:45
Spyre Therapeutics Research and Development Expense (Quarterly) : 60.41M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Tyra Biosciences, Inc. | 33.33M |
| Revolution Medicines, Inc. | 341.62M |
| Apellis Pharmaceuticals, Inc. | 76.96M |
| Replimune Group, Inc. | 52.87M |
| Savara, Inc. | 23.40M |